BRPI0412899A - composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos - Google Patents

composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos

Info

Publication number
BRPI0412899A
BRPI0412899A BRPI0412899-0A BRPI0412899A BRPI0412899A BR PI0412899 A BRPI0412899 A BR PI0412899A BR PI0412899 A BRPI0412899 A BR PI0412899A BR PI0412899 A BRPI0412899 A BR PI0412899A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
therapeutically effective
acceptable salts
Prior art date
Application number
BRPI0412899-0A
Other languages
English (en)
Inventor
Thomas Helleday
Nicola Curtin
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0317466.1A external-priority patent/GB0317466D0/en
Priority claimed from GB0408524A external-priority patent/GB0408524D0/en
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Publication of BRPI0412899A publication Critical patent/BRPI0412899A/pt
Publication of BRPI0412899B1 publication Critical patent/BRPI0412899B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

"COMPOSTO PARA INIBIR A ATIVIDADE DE PARP, USOS DE UMA QUANTIDADE TERAPêUTICA E UMA QUANTIDADE TERAPEUTICAMENTE EFETIVA DE UM COMPOSTO E DE SEUS SAIS FARMACEUTICAMENTE ACEITáVEIS, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA O TRATAMENTO DE CáNCER EM MAMìFEROS" A invenção refere-se aos derivados de lactama-indol tricíclicos e aos derivados de lactama-benzimidazol triacíclicos e ao seu uso na inibição da atividade da enzima PARP. A invenção também se refere ao uso destes compostos na preparação de medicamentos.
BRPI0412899-0A 2003-07-25 2004-07-23 Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático BRPI0412899B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use
GB0317466.1 2003-07-25
GB0408524.7 2004-04-16
GB0408524A GB0408524D0 (en) 2004-04-16 2004-04-16 Use
PCT/GB2004/003183 WO2005012305A2 (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors

Publications (2)

Publication Number Publication Date
BRPI0412899A true BRPI0412899A (pt) 2006-10-03
BRPI0412899B1 BRPI0412899B1 (pt) 2021-10-05

Family

ID=34117642

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412899-0A BRPI0412899B1 (pt) 2003-07-25 2004-07-23 Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático

Country Status (22)

Country Link
US (2) US7531530B2 (pt)
EP (1) EP1660095B1 (pt)
JP (2) JP5466814B2 (pt)
KR (1) KR101138471B1 (pt)
AT (1) ATE454893T1 (pt)
AU (1) AU2004261462B2 (pt)
BR (1) BRPI0412899B1 (pt)
CA (1) CA2533332C (pt)
CY (1) CY1110335T1 (pt)
DE (1) DE602004025123D1 (pt)
DK (1) DK1660095T3 (pt)
ES (1) ES2339663T3 (pt)
IL (1) IL173336A (pt)
MX (1) MXPA06000993A (pt)
NO (1) NO334610B1 (pt)
NZ (1) NZ544989A (pt)
PL (1) PL1660095T3 (pt)
PT (1) PT1660095E (pt)
RU (1) RU2404183C2 (pt)
SI (1) SI1660095T1 (pt)
WO (1) WO2005012305A2 (pt)
ZA (1) ZA200600679B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020488A (ko) * 2001-08-29 2003-03-10 강정훈 대나무 추출물을 유효성분으로 하는 화상치료용 조성물
CA2520997A1 (en) * 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
WO2005053662A1 (en) * 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
JP2008513436A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
EP2319847A3 (en) 2005-01-19 2012-06-20 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
NZ565654A (en) * 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
PL2209375T3 (pl) 2007-10-03 2014-12-31 Eisai Inc Związki, kompozycje i metody stosowania inhibitorów PARP
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
CA2705417A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
JP2011521618A (ja) * 2008-02-04 2011-07-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ仲介疾患を診断および治療する方法
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
RS55487B2 (sr) 2010-02-12 2024-06-28 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
DK2582847T3 (en) 2010-06-18 2016-12-19 Myriad Genetics Inc METHODS AND MATERIALS TO ASSESS loss of heterozygosity
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
WO2012071684A1 (en) 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivates，preparation processes and medical uses thereof
US20140051737A1 (en) * 2011-05-10 2014-02-20 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
EP4563709A3 (en) 2011-06-17 2025-09-03 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
SG10201605814QA (en) 2011-07-22 2016-09-29 Pacylex Pharmaceuticals Inc Synthetic lethality and the treatment of cancer
EP2794907B2 (en) 2011-12-21 2022-11-23 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
CA2864481C (en) 2012-02-23 2020-07-14 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
WO2013182645A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014037313A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
EP3693475A1 (en) 2013-04-05 2020-08-12 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
JP6877334B2 (ja) 2014-08-15 2021-05-26 ミリアド・ジェネティックス・インコーポレイテッド 相同組換え欠損を評価するための方法および材料
DK3182975T3 (da) 2014-08-22 2025-10-20 Pharma& Schweiz Gmbh Tabletter med høj doseringsstyrke af rucaparib
KR20160116831A (ko) 2015-03-31 2016-10-10 (주)아모레퍼시픽 코지산 유도체를 유효성분으로 포함하는 장수 유전자 활성화용 조성물
PL3325662T3 (pl) 2015-07-17 2024-02-26 Pacylex Pharmaceuticals Inc. Wyciszenie epigenetyczne nmt2
ES2879434T3 (es) 2015-07-23 2021-11-22 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
US20190055563A1 (en) * 2015-10-19 2019-02-21 Dana-Farber Cancer Institute, Inc. Polymerase q as a target in hr-deficient cancers
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2017087235A1 (en) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
KR102477372B1 (ko) 2016-04-01 2022-12-13 놈스 테크놀로지스, 인크. 인을 함유하는 개질된 이온성 액체
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
CN110300600A (zh) 2016-11-02 2019-10-01 伊缪诺金公司 利用抗体-药物缀合物和parp抑制剂的组合治疗
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018165615A1 (en) 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
US12121518B2 (en) 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
CA3096127A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
WO2019018432A1 (en) 2017-07-17 2019-01-24 NOHMs Technologies, Inc. ELECTROLYTES CONTAINING PHOSPHORUS
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
CN112334133A (zh) 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
MA54091A (fr) 2018-10-30 2021-09-15 Repare Therapeutics Inc Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230002487A (ko) 2020-04-28 2023-01-05 리젠 파마슈티컬스 아게 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
BR112023020615A2 (pt) 2021-04-08 2023-12-19 Incozen Therapeutics Pvt Ltd Inibidores de poli(adp-ribose) polimerase
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU686843B2 (en) * 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
HRP20010573B1 (en) * 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2520997A1 (en) * 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
WO2005053662A1 (en) 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物

Also Published As

Publication number Publication date
IL173336A (en) 2014-02-27
KR20060066067A (ko) 2006-06-15
MXPA06000993A (es) 2006-08-31
DK1660095T3 (da) 2010-05-25
WO2005012305A3 (en) 2005-04-07
JP5466814B2 (ja) 2014-04-09
ATE454893T1 (de) 2010-01-15
BRPI0412899B1 (pt) 2021-10-05
NO20060928L (no) 2006-02-24
AU2004261462A1 (en) 2005-02-10
RU2006105652A (ru) 2006-08-10
CA2533332A1 (en) 2005-02-10
KR101138471B1 (ko) 2012-04-25
US20070072841A1 (en) 2007-03-29
WO2005012305A2 (en) 2005-02-10
JP5580280B2 (ja) 2014-08-27
CY1110335T1 (el) 2015-01-14
HK1084602A1 (en) 2006-08-04
CA2533332C (en) 2012-01-10
US20050143370A1 (en) 2005-06-30
IL173336A0 (en) 2006-06-11
EP1660095B1 (en) 2010-01-13
US7531530B2 (en) 2009-05-12
PT1660095E (pt) 2010-04-19
AU2004261462B2 (en) 2010-04-22
ZA200600679B (en) 2011-08-31
NO334610B1 (no) 2014-04-22
EP1660095A2 (en) 2006-05-31
PL1660095T3 (pl) 2010-07-30
JP2012087135A (ja) 2012-05-10
DE602004025123D1 (en) 2010-03-04
US7351701B2 (en) 2008-04-01
SI1660095T1 (sl) 2010-05-31
JP2007533601A (ja) 2007-11-22
RU2404183C2 (ru) 2010-11-20
NZ544989A (en) 2009-10-30
ES2339663T3 (es) 2010-05-24

Similar Documents

Publication Publication Date Title
BRPI0412899A (pt) composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
BR0015051A (pt) Compostos inibidores tricìclicos de poli(adp-ribose) polimerase, seu sal farmaceuticamente aceitável, pró-droga, metabólito ativo, ou solvato, composição farmacêutica, método de inibição da atividade de parp de uma enzima e método de inibição da atividade de enzima parp em tecido de mamìfero
BR9906013A (pt) Derivados bicìclicos heteroaromáticos úteis como agentes anticancerìgenos
BRPI0108394B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BRPI0008614B8 (pt) composto inibidor tricíclico de poli(adp-ribose) polimerase, e composição farmacêuticas contendo tal composto.
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BR0209957A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BRPI0514357A (pt) combinações para o tratamento de doenças que envolvem a proliferação de células
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
WO2001039763A3 (en) Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BR0010938A (pt) Derivados da 13-metil eritromicina
NO20060612L (no) Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
BR0308108A (pt) Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0114100A (pt) Formulações de liberação controlada para administração oral

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CANCER RESEARCH TECHNOLOGY LIMITED (GB) , PFIZER I

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: CANCER RESEARCH TECHNOLOGY LIMITED

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. C07D 487/00

Ipc: C07D 487/00 (2011.01), A61P 35/00 (2011.01)

Free format text: PARA: INT. CL. C07D 487/00; A61P 35/00

Ipc: C07D 487/00 (2011.01), A61P 35/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2732 DE 16/05/2023 POR TER SIDO INDEVIDA.